News

Published on 11 Jan 2022 on Benzinga

The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory...

Article preview image

Here's a roundup of top developments in the biotech space over the last 24 hours:

BioAtla, Inc. (NASDAQ: BCAB) said it has entered into a clinical collaboration with Bristol-Myers Squibb Company (NYSE: BMY) to investigate its two lead CAB-antibody-drug conjugate candidates, BA3011 and BA3021, in combination with the latter's cancer immunotherapy Opdivo.

Read the rest of the article
NYSE.MYE price evolution
NASDAQ.NARI price evolution
NASDAQ.PLSE price evolution
NASDAQ.FUSN price evolution
NASDAQ.BDTX price evolution
NASDAQ.RPRX price evolution
NYSE.ATNM price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Royalty Pharma plc's (NASDAQ:RPRX) Stock Has Shown A Decent Performance: Have Financials A Role To...

Royalty Pharma's (NASDAQ:RPRX) stock up by 8.1% over the past three months. Given that stock pric...

Simply Wall St. via Yahoo Finance 30 Mar 2024
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months

Some stocks seem to hog the limelight, and that's understandable, to some extent. After all, stoc...

Motley Fool via Yahoo Finance 16 Feb 2024
Royalty Pharma plc (NASDAQ:RPRX) Q4 2023 Earnings Call Transcript

Royalty Pharma plc (NASDAQ:RPRX) Q4 2023 Earnings Call Transcript February 15, 2024 Royalty Pharm...

Insider Monkey via Yahoo Finance 16 Feb 2024
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight

Robust market share with a 58% stake in biopharmaceutical royalty transactions from 2012 through ...

GuruFocus.com via Yahoo Finance 16 Feb 2024
What Makes Royalty Pharma plc (RPRX) a Compelling Stock?

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equ...

Insider Monkey via Yahoo Finance 31 Jan 2024
Should You Sell Royalty Pharma plc (RPRX)?

TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid C...

Insider Monkey via Yahoo Finance 14 Dec 2023
Royalty Pharma plc (NASDAQ:RPRX) is a favorite amongst institutional investors who own 69%

Key Insights Given the large stake in the stock by institutions, Royalty Pharma's stock price mig...

Simply Wall St. via Yahoo Finance 26 Nov 2023
The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis

Strengths: Diverse portfolio with royalties on over 35 commercial products and a robust pipeline ...

GuruFocus.com via Yahoo Finance 9 Nov 2023
Are Royalty Pharma plc's (NASDAQ:RPRX) Mixed Financials Driving The Negative Sentiment?

With its stock down 10% over the past three months, it is easy to disregard Royalty Pharma (NASDA...

Simply Wall St. via Yahoo Finance 7 Sep 2023
Why Royalty Pharma (RPRX) Might Surprise This Earnings Season

Investors are always looking for stocks that are poised to beat at earnings season and Royalty Ph...

Zacks via Yahoo Finance 22 Jul 2023

Copyright Statfolio @ 2024

Social Accounts